Effect of Combined Endurance Training on ADL and Walking in COPD Patients

Recruiting now · Not applicable

Conditions studied: COPD

In brief

Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with related exercise intolerance and marked disability due to symptoms such as dyspnea and fatigue. Effort intolerance and exercise-induced symptoms cause marked impairment in completing activities of daily living (ADL). Pulmonary rehabilitation (PR), which has exercise as a major component, is considered a key treatment in the management of COPD since PR is effective in improving exercise tolerance, exercise-induced dyspnea and fatigue, and health-related quality of life. Rehabilitation is also effective in improving the time required to perform ADLs, reducing symptoms and disability. Studies show that rehabilitation protocols with upper limb exercises added to lower limb training are able to give additional benefits in terms of effort tolerance (endurance time at the arm ergometer and oxygen consumption) and reduction of dyspnea at iso-load. The primary aim of this study is to evaluate whether the combined "arm and leg" training modality, compared to a gold standard protocol -involving only the lower limbs training- is more effective in improving ADL performance in terms of reduction of exercise time for a specific test (GLITTRE test).

Key facts

Study ID

NCT05708443

Run by

Istituti Clinici Scientifici Maugeri SpA

People needed

36

Starts

2023-01-10

Expected to finish

2027-06-30

Last updated by the study team

2026-06-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• GOLD class 2-3 COPD
• Forced Expiratory Volume in the first second (FEV1) between 30% and 70% of the predicted value
• ability to walk and climb stairs without assistance
• stable clinical condition (pH > 7.35)

You may not qualify if…

• chronic respiratory insufficiency on long-term oxygen therapy (LTOT)
• severe orthopedic, neurological or cardiological comorbidities
• cognitive impairment
• recent exacerbation (within 15 days) requiring a change in therapy
• presence of lung disease other than COPD
• terminality

Where it is running

• ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Lumezzane — Lumezzane, Brescia, Italy (enrolling)
• ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Montescano — Montescano, Pavia, Italy
• ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Tradate — Tradate, Varese, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.